Skip to main content

Australia's CSL to start work on immunoglobulin product to treat COVID-19

Australian biotech firm CSL Ltd said on Wednesday it will start local development of an immunoglobulin product to treat serious cases of COVID-19, the disease caused by the novel coronavirus.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.